Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Balance Sheets

v3.23.3
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 8,057 $ 16,036
Investments in marketable debt securities 90,673 85,860
Prepaid expenses and other 3,915 3,014
Total current assets 102,645 104,910
Long-term assets:    
Investments in marketable debt securities 8,144 16,470
Right-of-use assets 1,933 2,054
Property and equipment, net 129 139
Deposits and other 148 148
Total assets 112,999 123,721
Current liabilities:    
Accounts payable 2,432 3,269
Accrued liabilities:    
Accrued clinical and other 2,557 507
Compensation and benefits 1,681 883
Current portion of operating lease liabilities 525 541
Total current liabilities 7,195 5,200
Long term liabilities:    
Operating lease liabilities, net of current portion 1,814 1,937
Embedded derivative liability 426 412
Total liabilities 9,435 7,549
Commitments and contingencies (Notes 5, 9 and 10)
Shareholders' equity:    
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 36,827 shares as of September 30, 2023 and June 30, 2023 37 37
Additional paid-in capital 379,320 377,471
Accumulated other comprehensive loss (284) (351)
Accumulated deficit (275,509) (260,985)
Total shareholders' equity 103,564 116,172
Total liabilities and shareholders' equity $ 112,999 $ 123,721